23 May 2013
Keywords: pharmion, vidaza, achieves, survival, benefit, mds, usa-based
Article | 17 December 2007
USA-based drugmaker Pharmion says that Phase III data from a trial of Vidaza (azacitidine for injection) in patients suffering higher-risk
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 December 2007
24 December 2007
22 May 2013
© 2013 thepharmaletter.com